Megakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant Mesothelioma

PURPOSE: Effective biomarkers for malignant mesothelioma (MM) are needed for clinical management and the development of mesothelin-targeted therapies. We evaluated serum megakaryocyte potentiating factor (MPF) as a biomarker predictive of treatment outcome in patients with MM and for developing meso...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JCO Precis Oncol
Main Authors: Cao, Liang, Yu, Yunkai, Thomas, Anish, Zhang, Jingli, Onda, Masanori, Meltzer, Paul, Hassan, Raffit, Pastan, Ira
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2018
Assuntos:
Original Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6201260/
https://ncbi.nlm.nih.gov/pubmed/30370397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.17.00282
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares